Navigation path

Guidance on temporary extraordinary measures related to medical device Notified Body audits during COVID-19 quarantine orders and travel restrictions
Stakeholder event on Biosimilar medicinal products 30-10-2019 FINAL AGENDA
A Snapshot of the Biosimilar Market Dynamics_IQVIA Report 2019
Market Dynamics from a DG COMP Perspective
Tools to Optimize Biosimilars Benefits from a Societal Perspective_HU Semmelweis University
Biosimilars in Slovakia_A Slovakian Union Health Insurance Fund Perspective
Update on Biosimilars in Germany_A German Physicians Association (KVWL) Perspective
Promoting the Use of Biosimilars in France_A FR Ministry of Solidarity & Health Perspective
How to Improve Early Access to Biosimilars_A Pharmacist's Perspective
Sustainable Procurement of Medicines_A Perspective from DG GROW
Biosimilars in the EU_A paradigm in Regulatory Science_A European Medicines Agency Perspective
Ways to Foster Biosimilars Access to Patients_A Clinician Perspective
How to Improve Early Access to Biosimilars_A Patients Organisation Perspective
How to Improve Early Access to Biosimilars_A European Specialist Nurses Organisation Perspective
Danish Experience with Biosimilars_A Danish Medicines Agency Perspective
Biosimilars in Hungary_A Hungarian Institute of Health Insurance Fund Perspective
List of organisations which attended the conference
2019 IQVIA Report - The Impact of Biosimilar Competition in Europe
Summary report - Multi-stakeholder Workshop on Biosimilar Medicinal Products
Guidance document 19 - Soother holders
Guidance doc 18 - Puffer balls and similar toys
Soft-filled toys with sequins – 6 March 2019
Support to the Evaluation of Regulation (EC) No 648/2004 (Detergents Regulation)
Notice to stakeholders - Withdrawal of the United Kingdom and EU legislation in the field of supplementary protection certificates for medicinal products and plant protection products
TSE/BSE
Results per page: 5 10 15 20 25 | Page 1 out of 2

Additional tools